Polly Bittle, APRN
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Amgen accounts for 79.8% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $22,331, 7.0 times the $3,175 reported in 2021. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $145.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$50K
- AstraZeneca$4K
- Calliditas Therapeutics US Inc.$3K
- Bayer$1K
- Mallinckrodt Hospital Products Inc.$1K
- Corcept Therapeutics$482
- plus $3K from 28 others
What the payments were for
- Consulting fees$9,76916%
- Speaking & faculty fees$36,06357%
- Travel & lodging$5,4929%
- Food & beverage$11,27218%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 219 | $50,093 |
| AstraZeneca | 43 | $3,551 |
| Calliditas Therapeutics US Inc. | 11 | $3,281 |
| Bayer | 33 | $1,101 |
| Mallinckrodt Hospital Products Inc. | 24 | $1,042 |
| Corcept Therapeutics | 13 | $482 |
| Travere Therapeutics, Inc. | 7 | $327 |
| GSK | 9 | $326 |
| Medtronic | 2 | $320 |
| Lilly USA, LLC | 3 | $260 |
| Otsuka America Pharmaceutical, Inc. | 11 | $211 |
| Lexicon Pharmaceuticals, Inc. | 11 | $205 |
| Boehringer Ingelheim | 9 | $193 |
| Esperion Therapeutics, Inc. | 2 | $137 |
| Novartis | 6 | $135 |
| Teva Pharmaceuticals USA, Inc. | 1 | $133 |
| Cvrx, Inc. | 1 | $122 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $120 |
| Argenx US, Inc. | 1 | $116 |
| ANI Pharmaceuticals, Inc. | 3 | $67 |
| Novo Nordisk | 2 | $57 |
| Ardelyx, Inc. | 3 | $57 |
| Vifor Pharma, Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Boston Scientific | 1 | $40 |
| Cycle Pharmaceuticals Inc | 2 | $25 |
| Akebia Therapeutics Inc | 1 | $23 |
| Renalytix AI, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Cormedix Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Fresenius USA Marketing, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,743 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $89,448 |
| Repatha SureclickEvolocumab | 35 | $42,954 |
| FarxigaDapagliflozin Propanediol | 32 | $37,525 |
| KerendiaFinerenone | 29 | $33,930 |
| JardianceEmpagliflozin | 22 | $28,839 |
| LokelmaSodium Zirconium Cyclosilicate | 39 | $21,427 |
| TrulicityDulaglutide | 13 | $20,093 |
| EliquisApixaban | 11 | $11,618 |
| Lanthanum Carbonate | 15 | $6,519 |
| JanuviaSitagliptin Phosphate | 11 | $6,241 |
| Clonidine | 32 | $5,335 |
| Sevelamer Carbonate | 20 | $3,492 |
| Nifedipine ErNifedipine | 84 | $2,443 |
| Calcium Acetate | 32 | $2,008 |
| Tacrolimus | 12 | $1,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $260 | $109,54080 claims |
| AstraZenecaFarxiga, Lokelma | $3,551 | $58,95271 claims |
| BayerKerendia | $1,101 | $33,93029 claims |
| Boehringer IngelheimJardiance | $193 | $28,83922 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $67 | $21913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Tampa
- Lewis HarringtonTampa$954K
- Marie Labadie-DegennaroTampa$66K
- Katharine WilliamsTampa$47K
- Candace DeberryTampa$46K
- Bailey BlankenshipTampa$42K
- Rasheeta ChandlerTampa$37K
- Rosaly TorresTampa$28K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.